Key Takeaways
- UCLA will test a new scope-cleaning machine following a superbug outbreak that caused three deaths
- The technology uses two-way water flow to dislodge bacteria from hard-to-clean areas
- Results from the trial are expected within months as hospitals seek better sterilization methods
UCLA is launching a trial of an innovative scope-cleaning machine after a deadly superbug outbreak claimed three lives at its medical center. The technology, developed by Arizona-based Langford IC Systems, represents a potential breakthrough in preventing lethal infections from contaminated medical scopes.
National Superbug Problem
Hospitals nationwide continue struggling with antibiotic-resistant infections linked to duodenoscopes – flexible tubes inserted down patients’ throats to treat digestive conditions. Multiple U.S. hospitals have reported outbreaks, prompting investigations by the FDA, Justice Department and Congress.
Dr. Raman Muthusamy, UCLA’s endoscopy director, explained the new machine will serve as an additional safety measure. “We are planning to study its effectiveness in the overall scope reprocessing protocol,” he said.
The hospital aims to determine if the technology provides long-term value in their cleaning processes. Results from the evaluation are expected within several months.
Technology Breakthrough
The cleaning system uses a fundamentally different approach than conventional washers. While standard equipment pushes water in one direction, Langford’s machine creates a powerful two-way flow that better dislodges trapped debris and bacteria.
Company founder Terry Langford, 71, said the technology received FDA clearance in 2011 but is only now being deployed for scope cleaning. “We have poured tens of millions of dollars into this. Now that it’s superbug time it will pay off,” he stated.
The system could potentially replace manual cleaning or eliminate the need for gas sterilization, which has limitations including high costs and potential scope damage.
Expert Caution and Market Readiness
Medical experts acknowledge the technology deserves evaluation but urge caution until effectiveness is proven. “They have an interesting idea if it really works, but I would be cautious,” said Lawrence Muscarella, a hospital safety consultant.
The small company, with just five employees, partners with Massachusetts-based Proven Process Medical Devices for manufacturing. Hospitals face no upfront costs – Langford charges $35 per use.
With scope redesigns not imminent, this trial represents a critical step in addressing a persistent healthcare safety challenge.
